Navigation Links
Professor collaborates on most comprehensive analyses of NSAIDs and coxibs
Date:5/30/2013

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of the Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs (NSAIDs), which include cyclo-oxygenase-2 inhibitors (coxibs).

Hennekens and colleagues from around the world, under the direction of the Clinical Trial Service and Epidemiology Studies Unit at the University of Oxford, conducted a world-wide meta-analyses using individual participant data from 280 trials of NSAIDs vs. placebo and 474 trials of NSAID vs. another NSAID, which involved a total of 353,809 participants and a total of 233,798 person-years. These results address risks and benefits of drugs used for relief of inflammatory arthritis including cardiovascular disease and other relevant outcomes such as gastrointestinal effects.

"The vascular risks of high-dose diclofenac and ibuprofen are comparable to coxibs, while high-dose naproxen is associated with less vascular risk than other NSAIDs," said Hennekens. "Although NSAIDs increase vascular and gastrointestinal risks, their magnitude can be predicted, which may help guide clinical decision-making."

David J. Bjorkman, MD, MSPH, dean of the Charles E. Schmidt College of Medicine at FAU and a gastroenterologist noted that "these are the most comprehensive analyses ever conducted of the benefits and risks of NSAIDs, which include coxibs, and should help guide healthcare providers in their prescribing patterns."

Hennekens concluded that "from a clinical and policy perspective, the available data suggest that for relief of pain of inflammatory arthritis, naproxen may have the best benefit-to-risk ratio on cardiovascular disease (CVD). In contrast to naproxen, other traditional NSAIDS and coxibs confer similar moderately increased risks of CVD. At present, individual clinical judgments about coxibs and nonselective NSAIDs should not be limited to risks of CVD. They should also include concerns about non-CVD risks, such as gastrointestinal bleeding and other benefits, including improved quality of life resulting from decreases in impairment from musculoskeletal pain syndromes."

Science Watch ranked Hennekens as the third most widely cited medical researcher in the world from 1995-2005, and five of the top 20 were his former trainees and/or fellows. In addition, in 2012 Science Heroes, ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives.


'/>"/>

Contact: Gisele Galoustian
ggaloust@fau.edu
561-985-4615
Florida Atlantic University
Source:Eurekalert

Related medicine news :

1. Louisiana Tech University professor earns NSF Early Career Development grant
2. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
3. Louisiana Tech biomedical engineering professor earns recognition, funding for research
4. Women professorships low in some Scandinavian universities due to sexism
5. President Obama names SF State math professor a top young scientist
6. From textbook to flexbook: Professor uses new collaborative tool in the classroom
7. IHME professor named first health measurement winner of prestigious innovation award
8. Guys, take note: Male birth control pill may be ready soon, says Texas A&M professor
9. UBC professor wins Canadas top pharmaceutical research award
10. Huddersfield professors ground-breaking research shows just how well the 2012 Games were run
11. Grove Professor receives $1.5MM to study breast cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... for life science companies, has achieved ISO 17100:2015 certification following a comprehensive ... 17100 is the globally recognized standard that establishes guidance for critical processes ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud to ... Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment ... to address the limitations of fatigue monitoring technologies within the mining industry. Today ...
(Date:1/23/2017)... ... ... boards have been around since at least the 1950s and are a great way to ... balance board to use a patent-pending design featuring high-pressure inflation technology and drop-stitch materials. ... skill-level adjustable for all ages and abilities. The board can be rolled up when ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and ... the benefits of making new water infrastructure a number one priority. “As we usher ... expect water infrastructure to become a top priority of our new political change agents.” ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Living (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector ... discussion, moderated by Inside Indiana Business host Gerry Dick, will feature an employer ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 MouthWatch LLC announced today that its flagship ... the best intraoral camera on DentalCompare,s list of Top ... The #1 product was the CollaPlug Absorbable Collagen Wound ... was "…incredibly popular because it is by far the most ... sticker price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)... TORONTO , Jan. 23, 2017 ... both 510(k) clearance from the U.S. Food and ... from Health Canada enabling the North American commercial ... (MIGS™) system for spine surgery, the 7D Surgical ... employs cutting-edge 3D optical technologies and machine vision ...
(Date:1/23/2017)... 2017 Research and Markets has announced the addition ... Product - Forecast to 2025" report to their offering. ... Report Highlights: ... to identify the investment opportunities Market forecasts till 2025, ... market trends across the business segments, Regions and Countries ...
Breaking Medicine Technology: